Waters (WAT) Hisse Özeti
Waters Corporation Asya, Amerika ve Avrupa'da analitik iş akışı çözümleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 1/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
WAT Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Waters Corporation Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$376.89 |
| 52 Haftanın En Yüksek Seviyesi | US$414.15 |
| 52 Haftanın En Düşük Seviyesi | US$275.05 |
| Beta | 1.2 |
| 1 Aylık Değişim | 11.30% |
| 3 Aylık Değişim | 30.34% |
| 1 Yıllık Değişim | 6.19% |
| 3 Yıllık Değişim | 43.88% |
| 5 Yıllık Değişim | 7.32% |
| Halka arzdan bu yana değişim | 9,867.34% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 18
WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside
Analysts maintained their $460.00 price target on Waters, citing relatively steady assumptions around revenue growth, profit margin, and future P/E, which offset the slightly higher discount rate in their valuation work. What’s in the News for Waters Waters launched the TA Instruments Coin Cell Differential Scanning Calorimeter, combining thermal, evolved gas, and electrochemical analysis in a single experiment to support earlier insights into battery thermal runaway and reduce cell teardown time by over 90% (source: company announcement, 9 June 2026).Analiz Makalesi • Jun 16
Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance
Waters (WAT) is in focus after launching its BioResolve Peptide and GTxResolve Lipid columns and securing FDA 510(k) clearance for the BD BACTEC FXI Culture System, developments that expand its biopharma and diagnostics footprint. See our latest analysis for Waters. Despite the product launches and diagnostics clearance, Waters’ share price shows mixed momentum, with a 30 day share price return of 9.51% and a 90 day share price return of 22.20%, while the 1 year total shareholder return sits...Recent updates
Anlatı Güncellemesi • Jun 18
WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside
Analysts maintained their $460.00 price target on Waters, citing relatively steady assumptions around revenue growth, profit margin, and future P/E, which offset the slightly higher discount rate in their valuation work. What’s in the News for Waters Waters launched the TA Instruments Coin Cell Differential Scanning Calorimeter, combining thermal, evolved gas, and electrochemical analysis in a single experiment to support earlier insights into battery thermal runaway and reduce cell teardown time by over 90% (source: company announcement, 9 June 2026).Analiz Makalesi • Jun 16
Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance
Waters (WAT) is in focus after launching its BioResolve Peptide and GTxResolve Lipid columns and securing FDA 510(k) clearance for the BD BACTEC FXI Culture System, developments that expand its biopharma and diagnostics footprint. See our latest analysis for Waters. Despite the product launches and diagnostics clearance, Waters’ share price shows mixed momentum, with a 30 day share price return of 9.51% and a 90 day share price return of 22.20%, while the 1 year total shareholder return sits...Anlatı Güncellemesi • Jun 03
WAT: New Omics Platforms And Buybacks Will Support Future Upside
Analysts have trimmed their price target for Waters to $460, reflecting slightly higher assumed discount rates, modestly adjusted long term revenue growth and profit margin expectations, and a lower future P/E multiple in their updated models. What's in the News Waters launched the Cyclic IMS P20 Mass Spectrometer, a structural and spatial omics platform using multipass Cyclic Ion Mobility Spectrometry and advanced fragmentation and imaging techniques, aimed at earlier detection of disease signals and more detailed molecular visualization.Analiz Makalesi • May 19
Earnings Troubles May Signal Larger Issues for Waters (NYSE:WAT) Shareholders
Investors weren't pleased with the recent soft earnings report from Waters Corporation ( NYSE:WAT ). We did some...Anlatı Güncellemesi • May 18
WAT: New Product Launches And Completed Buybacks Will Support Future Upside
Analysts now set a slightly higher price target for Waters at about $478, up from about $470, reflecting updated views on its fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Waters issued earnings guidance for the second quarter of 2026, with expected total revenue between US$1.616b and US$1.631b, and for full year 2026, with expected total revenue between US$6.405b and US$6.455b on a reported basis (Corporate guidance).Anlatı Güncellemesi • May 01
WAT: New Instrument Launches And Reorganized Divisions Will Support Future Upside
Analysts have trimmed their price target on Waters from $480 to $470, citing updated assumptions for significantly higher revenue growth at 37.91%, a profit margin of 17.88%, a prospective P/E of 47.70 and a discount rate of 7.89%. What's in the News Waters plans to globally launch the omniDAWN Multi Angle Light Scattering Photometer in summer 2026, targeting UHPLC and UPLC workflows for absolute molar mass and size measurements across complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials (Key Developments).
Anlatı Güncellemesi • Apr 17
WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check
Analysts have kept their price target for Waters steady at $330.00, citing updated assumptions for slightly higher revenue growth, a wider profit margin, and a higher future P/E multiple as the key drivers behind the unchanged fair value view. What's in the News Launched the Waters omniDAWN Multi-Angle Light Scattering Photometer for UHPLC and UPLC workflows, targeting absolute molar mass and size measurements for complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials.
Anlatı Güncellemesi • Apr 03
WAT: New Four Division Model And Materials Focus Will Support Higher Profitability
Analysts have reduced their price target on Waters by about $5 to $393, reflecting small adjustments to fair value assumptions, discount rate, revenue growth, profit margin and future P/E inputs. What's in the News Waters launched the TA Instruments ARES-G3 Rheometer, a next generation system that captures up to 25,000 data points per second, aims to shorten standard test times by up to 80%, and is available for order as part of the materials characterization portfolio (Key Developments).Anlatı Güncellemesi • Mar 20
WAT: New Four Division Model Will Support Higher Long Term Profitability
Analysts have kept their price target for Waters steady at $398.05. This reflects updated views on a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E assumption.Seeking Alpha • Mar 10
Waters: Doing Well, Acquired Activities Not So Much
Summary Waters' shares have retreated to the $300 level, presenting a renewed buying opportunity after initial post-acquisition gains evaporated. The $17.5B acquisition of Becton, Dickinson's Biosciences & Diagnostics Solutions expands Waters scale, though acquired business growth appears soft versus initial expectations. Waters guides 2026 sales to $6.405–$6.455B and adjusted EPS to $14.30–$14.50, reflecting early synergies and manageable leverage. At 21x earnings, Waters is not historically cheap, but synergy potential and deleveraging support a more upbeat outlook at current levels. Read the full article on Seeking AlphaAnlatı Güncellemesi • Mar 05
WAT: New Four Division Structure Will Support Higher Long Term Earnings
Analysts have nudged their price target for Waters higher to $398.05 from $394.68, reflecting updated assumptions that combine a higher revenue growth outlook, a lower projected profit margin, and a richer future P/E multiple. What's in the News Waters has closed a transaction and reorganized into four divisions, aligning its operations with high volume testing in regulated applications and adjacent markets such as therapeutics, food, environmental testing, and specialty diagnostics (Key Developments).Anlatı Güncellemesi • Feb 19
WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now
Analysts now mark their price target for Waters at $330, down from $349, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E that change their overall valuation framework. What's in the News Waters closed a transaction and reorganized into four divisions focused on high-volume testing and adjacent markets, now grouped as Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences (company announcement).Anlatı Güncellemesi • Feb 05
WAT: New Detector Launch And Higher Margins Will Likely Disappoint Optimists
Analysts have modestly lifted their price target for Waters to about $349, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E as the key drivers of this small adjustment from roughly $348.15. What's in the News Waters has scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat in the United States (Key Developments).Anlatı Güncellemesi • Jan 22
WAT: New Detector Launch And Stable Margins Will Support Future Upside
Analysts kept their price target for Waters steady at US$480.00, with only very small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, reflecting fine-tuning rather than a major shift in their view. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held via proxydocs.com/wat in the United States (company event filing).Anlatı Güncellemesi • Jan 08
WAT: Higher Margins And New Product Launch Will Support Future Upside
Analysts have lifted their price target on Waters to US$480 from about US$424, citing updated assumptions for slightly higher revenue growth, profit margins near 26%, and a modestly higher future P/E multiple. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat (Special/Extraordinary Shareholders Meeting).Analiz Makalesi • Jan 04
Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)
Key Insights Waters' estimated fair value is US$362 based on 2 Stage Free Cash Flow to Equity Waters' US$382 share...Anlatı Güncellemesi • Dec 25
WAT: Future Product Expansion Will Likely Fail To Justify Current Optimism
Analysts have raised their price target on Waters from 300.00 dollars to 348.15 dollars, citing slightly stronger expectations for revenue growth, profit margins, and future valuation multiples. What's in the News Launched a new Charged Aerosol Detector optimized for Empower Software, expanding capabilities for measuring analytes with little or no UV absorption across pharmaceuticals, food, and environmental testing, with shipments expected by April 2026 (company product announcement).Anlatı Güncellemesi • Dec 10
WAT: Future Margin Gains And New Instruments Will Support Measured Earnings Outlook
Narrative Update on Waters Analysts have modestly raised their price target on Waters by approximately $6 per share, reflecting slightly lower discount rate assumptions, a small improvement in projected profit margins, and a marginally higher future P/E multiple that together support a higher fair value estimate. What's in the News Launched a new Charged Aerosol Detector, purpose built for Empower chromatography software, expanding Waters portfolio of LC detectors and strengthening its position in compliant, high sensitivity analysis for low UV analytes, with shipments expected by April 2026 (Key Developments) Unveiled the Xevo Charge Detection Mass Spectrometer to enable high resolution characterization of very large biomolecules that are central to next generation therapeutics, leveraging technology acquired from Indiana University and Megadalton Solutions (Key Developments) Raised full year 2025 guidance and now expects constant currency sales growth of 6.7% to 7.3% and GAAP EPS of 11.10 to 11.20 dollars per diluted share (Key Developments) Issued new guidance for the fourth quarter of 2025, targeting constant currency sales growth of 5.0% to 7.0% and GAAP EPS of 4.10 to 4.20 dollars per diluted share (Key Developments) Completed its multi year share repurchase program announced in January 2019, buying back more than 15.1 million shares for approximately 3.8 billion dollars in total consideration (Key Developments) Valuation Changes The fair value estimate has risen slightly to approximately $395 per share from about $389 per share, reflecting modest valuation upside.Anlatı Güncellemesi • Nov 26
WAT: Future Margins And Expanded Guidance Will Offset Slower Revenue Trends
Narrative Update on Waters: Analyst Price Target Revision Analysts have raised their price target for Waters, increasing the fair value estimate by $5.71 to $388.58. This revision is attributed to improved profit margin projections, even as revenue growth expectations have slowed.Anlatı Güncellemesi • Nov 07
WAT: Revenue Momentum And Expanded Guidance Will Balance Margin Risks Ahead
Analysts have raised their price target for Waters from $355.74 to $382.87. They cite significantly higher expected revenue growth, which outweighs a slight decrease in projected profit margins.Anlatı Güncellemesi • Oct 23
Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities
Narrative Update on Waters Analysts have slightly raised their price target for Waters from $351.07 to $355.74. This change is attributed to modest improvements in projected revenue growth and fair value estimates.Anlatı Güncellemesi • Oct 09
Pharmaceutical R&D And Merger Will Unlock Future Market Potential
Analysts have raised their price target for Waters to $351.07 from $347.14, citing expectations of stronger profit margins and steady revenue growth ahead. What's in the News Waters Corporation raised its earnings guidance for the full year 2025 and projects constant currency sales growth between 5.5% and 7.5%.Analiz Makalesi • Sep 19
Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)
Waters Corporation's ( NYSE:WAT ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right now...Anlatı Güncellemesi • Sep 04
Pharmaceutical R&D And Merger Will Unlock Future Market Potential
With no changes in revenue growth expectations or discount rate, Waters’ fair value estimate remains stable, as reflected in the unchanged consensus analyst price target of $350.24. What's in the News Completed buyback program with 15,195,844 shares repurchased for $3,790.62 million, representing 22.96% of shares.Analiz Makalesi • Jul 24
Are Investors Undervaluing Waters Corporation (NYSE:WAT) By 36%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Waters fair value estimate is US$465 Waters is estimated to be...Analiz Makalesi • Jul 06
These 4 Measures Indicate That Waters (NYSE:WAT) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Feb 21
Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern
Summary Waters Corp reported better-than-expected Q4'24 and FY'24 results, driven by strong performance in academia, government, and pharma segments, despite FX headwinds impacting gross margins. The company anticipates continued growth in 2025, with projected revenue growth between 4.5% and 7%, supported by emerging markets like India and high-growth areas like GLP-1 and PFAS testing. Risks include elevated valuations and limited opportunities for cash deployment, making buybacks less attractive; current valuation appears challenging compared to historical averages and peers. I rate Waters Corp as a 'hold' due to solid recovery and growth potential, but caution investors to consider the premium pricing relative to value. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
Weighing In On Waters Corporation: Facing A Valuation Headwind
Summary Today, we take a more in-depth look at Waters Corporation, which provides analytical workflow solutions, primarily to the Pharma and Industrial industries. WAT stock has surged 35% since July lows, but analysts are growing increasingly cautious due to valuation concerns, with mixed ratings and tepid price targets. From a historical perspective, the equity now trades at the very top of its historical P/S and P/E ratios. Can WAT shares rally with this valuation headwind? An analysis of Waters Corporation follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Waters Corp: Short Reinvestment Runway Diminishes High Multiples
Summary Despite a 13% stock appreciation, I maintain a neutral stance on Waters Corporation due to factors outlined in this report. Q3 FY'24 results show mixed regional performance, with China sales still a drag on performance. Opportunities to redeploy surplus funds at an advantage appear limited, reducing compounding ability. Read the full article on Seeking AlphaSeeking Alpha • Aug 15
Waters Corp.: Embedded Expectations High Under Present Conditions
Summary Waters continues to present with high-quality business characteristics, including high returns on capital employed and loads of freely available cash. Embedded expectations remain exquisitely high, calling for outsized performance in a time when business returns may be contracting. Present multiples demand high compounding rate of operating capital, which reduces the margin of safety. Reiterate hold. Read the full article on Seeking AlphaSeeking Alpha • May 24
Waters Corporation: Still Struggling A Bit
Summary Waters Corporation reported mediocre first quarter results with the top and bottom line declining. According to fiscal 2024 guidance, the company is still not expecting growth but due to the wide economic moat, we should be optimistic for long-term growth. At this point, Waters Corporation is fairly valued at best and still not a great investment. Read the full article on Seeking AlphaHissedar Getirileri
| WAT | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | 6.0% | 6.4% | -2.5% |
| 1Y | 6.2% | 12.5% | 20.1% |
Getiri vs. Endüstri: WAT geçen yıl % 12.5 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: WAT geçen yıl % 20.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| WAT volatility | |
|---|---|
| WAT Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: WAT son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: WAT 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1958 | 7,900 | Udit Batra | www.waters.com |
Waters Corporation, Asya, Amerika ve Avrupa'da analitik iş akışı çözümleri sunmaktadır. Şirket, Waters ve TA olmak üzere iki segmentte faaliyet göstermektedir. Şirket, sıvı kromatografisinin yanı sıra kütle spektrometresi (MS) teknoloji sistemleri tasarlar, üretir, satar ve hizmet verir ve kromatografi kolonları ve diğer sarf malzemeleri dahil olmak üzere ürünleri destekler.
Waters Corporation Temel Bilgiler Özeti
| WAT temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$36.25b |
| Kazançlar(TTM) | US$449.63m |
| Gelir(TTM) | US$3.77b |
82.3x
F/K Oranı9.8x
P/S OranıWAT aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| WAT gelir tablosu (TTM) | |
|---|---|
| Gelir | US$3.77b |
| Gelir Maliyeti | US$1.69b |
| Brüt Kâr | US$2.08b |
| Diğer Giderler | US$1.63b |
| Kazançlar | US$449.63m |
Son Raporlanan Kazançlar
Apr 04, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 4.58 |
| Brüt Marj | 55.15% |
| Net Kâr Marjı | 11.93% |
| Borç/Özkaynak Oranı | 34.3% |
WAT uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/25 22:31 |
| Gün Sonu Hisse Fiyatı | 2026/06/25 00:00 |
| Kazançlar | 2026/04/04 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Waters Corporation 40 Bu analistlerden 21, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |